44.90NOK-2.18%Mkt Cap: 201.08M NOKP/E: —Last update: 2026-06-01
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap201.08M NOK
Enterprise Value31.51M NOK
Revenue (TTM)28.07M NOK
Gross Profit28.07M NOK
Net Income (TTM)-155.07M NOK
Revenue/Share0.2270 NOK
Last Price44.90 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees44
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013711713
Valuation
P/E (Trailing)—
P/E (Forward)-2.22
PEG—
EV/EBITDA-0.21
EV/Revenue1.12
P/S7.32
P/B140.37
EPS (TTM)-124.46
EPS (Forward)-20.68
52W Range
40.105% of range134.25
52W High134.25 NOK
52W Low40.10 NOK
Profitability
Gross Margin100.00%
Oper. Margin-659.95%
EBITDA Margin0.00%
Profit Margin-673.13%
ROE-105.98%
ROA-75.66%
Growth
Revenue Growth100.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.87M NOK
CapEx (TTM)119.00K NOK
FCF Margin-303.52%
FCF Yield-42.37%
Net Debt-174.05M NOK
Net Debt/EBITDA1.16
Balance Sheet
Debt/Equity0.02
Current Ratio3.23
Quick Ratio3.20
Book Value/Sh0.3270 NOK
Cash/Share39.66 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJan 19, 2026
Analyst Consensus
Rating—
Target (Mean)59.50 NOK
Target Range49.00 NOK – 70.00 NOK
# Analysts2
Ownership
Shares Out.4.48M
Float3.00M
Insiders26.77%
Institutions38.70%
Technical
SMA 5047.11 (-4.7%)
SMA 20056.27 (-20.2%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)3.67K
Avg Vol (10d)3.33K
Technical Indicators
RSI (14)44.8
MACD-0.3864
MACD Signal-0.1748
MACD Hist.-0.2116
BB Upper49.76 NOK
BB Middle47.16 NOK
BB Lower44.56 NOK
BB Width11.01%
ATR (14)1.996 NOK
Vol Ratio (20d)0.13x